New Consensus Statement from AACE and ACE on Insulin Pump Therapy

thumbnail

This week, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) updated their consensus statement on insulin pump therapy. If you or someone in your life lives with diabetes, you may be wondering: 1) what is a consensus statement and 2) what does this mean for me?

First, a consensus statement is a comprehensive analysis by a panel of experts on a scientific or medical issue. It’s typically developed after a consensus conference where presentations are made on the topic under review.

So, what does this mean for you and others in the diabetes online community? Well, these consensus statements affect you more than you might think. They serve as a way for experts in the field of endocrinology to share the latest information and best practices on a particular topic (in this case, insulin pump therapy) with physicians throughout the country and guide them in treating their patients – people like you. In addition, the support of prestigious physician organizations like AACE helps promote access to these therapies for people who need them.

So, what’s new in the updated consensus statement? Here are a few of the highlights:

  • AACE and ACE continue to support insulin pump therapy for people with type 1 diabetes, and highlight MiniMed 530G with Enlite as a primary example of an insulin pump advancement that has significant clinical benefit.
  • The two organizations also recognize the clinical value of insulin pumps in improving glucose control for those with intensively managed insulin-dependent type 2 diabetes.
  • In addition, they go on to state that the current criteria applied by some payers to qualify people with type 2 diabetes for insulin pump therapy are not justified. This is important because, while the majority of private payers provide coverage for insulin pumps for both type 1 and type 2 patients, some restrict access to many people with type 2 diabetes by requiring that they be C-peptide negative or have other markers of islet autoimmunity. C-peptide is a blood test that indicates whether insulin is being produced by the pancreas. However, it does not show insulin resistance, which characterizes many patients with type 2 diabetes. The support of AACE and ACE helps ensure access to insulin pumps for people who need them.

We believe this is very important news for families impacted by both type 1 and type 2 diabetes. Please join us in thanking AACE and ACE for the important role that they play in the lives of people with diabetes!

IMPORTANT SAFETY INFORMATION

Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems. MiniMed 530G with Enlite is intended for the delivery of insulin and continuous glucose monitoring for the management of diabetes mellitus by persons 16 years of age or older who require insulin.

Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.

The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a home glucose meter. A confirmatory fingerstick is required prior to making adjustments to diabetes therapy. MiniMed 530G with Enlite is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Threshold Suspend alarm and take measures to prevent or treat hypoglycemia themselves.

Please visit MedtronicDiabetes.com/isi for more details.

Tags: , , , , , , ,
Latest Comments
  1. Kitty Castellini
    • Sara Tilleskjor Sara Tilleskjor
  2. Karen LeBoulch
    • Sara Tilleskjor Sara Tilleskjor

Post A Comment

Your email address will not be published. Required fields are marked *

Current ye@r *